Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

作者: Claire M Shipman , Michael J Rogers , Jane F Apperley , R Graham G Russell , Peter I Croucher

DOI: 10.1046/J.1365-2141.1997.2713086.X

关键词: Cell cultureBisphosphonateClodronic acidPamidronic acidImmunologyCancer researchProgrammed cell deathBiologyApoptosisCell cycleMultiple myeloma

摘要: Bisphosphonates are in widespread use to prevent bone resorption a number of metabolic and tumour-induced diseases including multiple myeloma. Recent reports suggest that bisphosphonate treatment may be associated with an increase patient survival, raising the possibility these compounds have direct effect on tumour cells. We investigated whether bisphosphonates clodronate, pamidronate YM175 can directly affect human myeloma cell lines U266-B1, JJN-3 HS-Sultan vitro. The cycle progression was examined using flow cytometry. ability induce apoptosis determined basis changes nuclear morphology DNA fragmentation. Pamidronate more potent bisphosphonate, YM175, significantly decreased (P < 0.001) also caused cells arrest S-phase line. Both proportion altered (P < 0.05) fragmented DNA, characteristic apoptosis, both In contrast, clodronate had little did not cause at concentrations examined. These data raise some could anti-tumour effects vivo.

参考文章(27)
Michael J. Rogers, R. Graham G. Russell, Mechanisms of Action of Bisphosphonates as Inhibitors of Bone Resorption Medical Intelligence Unit. pp. 147- 177 ,(1996) , 10.1007/978-3-662-22505-9_7
A.H. Wyllie, J.F.R. Kerr, A.R. Currie, Cell death : the significance of apoptosis International Review of Cytology-a Survey of Cell Biology. ,vol. 68, pp. 251- 306 ,(1980) , 10.1016/S0074-7696(08)62312-8
Gregory R. Mundy, Brendan F. Boyce, Kenneth R. Wright, Akira Sasaki, Toshiyuki Yoneda, Mark Chapman, Beryl Story, Rogely Boyce, Bisphosphonate Risedronate Reduces Metastatic Human Breast Cancer Burden in Bone in Nude Mice Cancer Research. ,vol. 55, pp. 3551- 3557 ,(1995)
Taina Taube, Monique N. C. Beneton, Eugene V. McCloskey, Susan Rogers, Mike Greaves, John A. Kanis, Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption European Journal of Haematology. ,vol. 49, pp. 192- 198 ,(2009) , 10.1111/J.1600-0609.1992.TB00046.X
G A Rodan, H A Fleisch, Bisphosphonates: mechanisms of action. Journal of Clinical Investigation. ,vol. 97, pp. 2692- 2696 ,(1996) , 10.1172/JCI118722
M Sato, W Grasser, N Endo, R Akins, H Simmons, D D Thompson, E Golub, G A Rodan, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation. ,vol. 88, pp. 2095- 2105 ,(1991) , 10.1172/JCI115539
Reino Lahtinen, Markku Laakso, Ilmari Palva, Inkeri Elomaa, Pekka Virkkunen, Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma The Lancet. ,vol. 340, pp. 1049- 1052 ,(1992) , 10.1016/0140-6736(92)93075-X
Gabri van der Pluijm, Hans Vloedgraven, Ermond van Beek, Lianne van der Wee-Pals, Clemens Löwik, Socrates Papapoulos, Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Journal of Clinical Investigation. ,vol. 98, pp. 698- 705 ,(1996) , 10.1172/JCI118841